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2 Spinal Muscular Atrophy (SMA) occurs as a result of cell-ubiquitous depletion of the essential SMN 
3 protein. Characteristic disease pathology is driven by a particular vulnerability of the ventral motor 
4 neurons of the spinal cord to decreased SMN. Perhaps not surprisingly, many other organ systems 
5 are also impacted by SMN depletion. The normal kidney expresses very high levels of SMN protein, 
6 equivalent to those found in the nervous system and liver, and levels are dramatically lowered by 
7 ~90-95% in mouse models of SMA. Taken together these data suggest that renal pathology may be 
8 present in SMA. We have addressed this using an established mouse model of severe SMA. Nephron 
9 number, as assessed by gold standard stereological techniques, was significantly reduced. In 
10 addition, morphological assessment showed decreased renal vasculature, particularly of the 
11 glomerular capillary knot, dysregulation of nephrin and collagen IV, and ultrastructural changes in 
12 the trilaminar filtration layers of the nephron. To explore the molecular drivers underpinning this 
13 process, we correlated these findings with quantitative PCR measurements and protein analyses of 
14 Glial Cell-Line Derived Neurotrophic Factor (GDNF), a crucial factor in ureteric bud branching and 
15 subsequent nephron development. GDNF levels were significantly reduced at early stages of disease 
16 in SMA mice. Collectively, these findings reveal significant renal pathology in a mouse model of 
17 severe SMA, further reinforcing the need to develop and administer systemic therapies for this 
18 neuromuscular disease.
































































2 Spinal Muscular Atrophy (SMA), an autosomal recessive condition, is a leading global genetic cause 
3 of infant disability. As a consequence of mutation of the Survival Motor Neuron 1 gene (SMN1), low 
4 cellular levels of the essential and cell-ubiquitously expressed survival motor neuron protein (SMN) 
5 are produced (1). In humans, this essential protein is expressed by two almost identical genes; 
6 telomeric SMN1 and centromeric SMN2. While SMN1 produces approximately 90% of functional, full 
7 length SMN protein, SMN2, which differs only marginally but results in alternative splicing of exon 7, 
8 produces only ~10% of full length SMN (2). In SMA, a deletion or loss-of-function mutation of the 
9 SMN1 gene results in a significant loss of SMN. Low protein levels produced by SMN2 ensure that 
10 the condition is not embryonically lethal, but rather gives rise to characteristic SMA pathology; 
11 degeneration of lower alpha motor neurons, leading to skeletal muscle denervation and atrophy (3). 
12
13 Despite the selective vulnerability of motor neurons to low levels of SMN, the ubiquitous decrease in 
14 expression results in a systemic presentation. In addition to characteristic lower motor neuron 
15 death, non-neuromuscular pathologies have been described in both patients and animal models (4), 
16 including, but not limited to, defects in the cardiovascular system (5–9), lungs (10), liver (11–13), 
17 spleen (14,15), pancreas (16) and gastrointestinal system (17).
18
19 Expression of SMN in the adult human kidney is high, with similar levels to those found in the CNS 
20 and liver (18), both of which are significantly impacted in SMA. In mice, normal renal SMN 
21 expression is high in comparison with other peripheral organs, while severe SMA mouse models 
22 exhibit a dramatic 90-95% reduction of SMN protein in kidney, which further decreases as the 
23 disease progresses (19). Data from SMA patients revealed histopathological abnormalities including 
24 tubular injury and fibrosis, and abnormal serum profiles, suggesting impaired kidney function and 
25 renal tubular dysfunction (20). Moreover, clinical trials have highlighted cases of proteinuria in SMA 
26 patients prior to any drug treatment, indicating compromised renal function (21). However, these 































































1 studies shed little or no light on the cellular and/or molecular pathways involved. Importantly, the 
2 highly vascular kidneys develop almost completely prior to birth, and nephrogenesis cannot be re-
3 initiated following its completion in the late embryonic/ early postnatal period (22,23).
4
5 Life changing treatments are now either available: antisense oligonucleotide Nusinersen (Spinraza, 
6 Biogen, Cambridge, MA); or are becoming available: gene therapy Onasemnogene abeparvovec 
7 Zolgensma (AveXis, Novartis, Chicago, IL) for affected patients, and deliver significant improvements 
8 in survival and quality of life (24). With the CNS as primary target, the ability of these therapies to 
9 address systemic pathologies (25,26), and particularly those which develop very early in life, remains 
10 largely unknown. By treatment of the neuronal pathology alone, it is likely that previously 
11 undiagnosed systemic defects may later arise in patients with extended survival. In particular, renal 
12 pathology, which may have been masked in early age, may surface due to cumulative renal stress as 
13 a result of increased blood volume and higher filtration needs in later life.
14
15 To characterise the cellular and molecular consequences of SMN deficiency on the renal system, we 
16 carried out a detailed morphological and molecular study of the kidney in the Taiwanese mouse 
17 model of severe SMA. We report significant structural and ultrastructural abnormalities, with a 
18 dramatic reduction in nephron number in the early postnatal kidney of SMA mice. These changes 
19 were associated with early onset pathology, namely glomerular sclerosis. In addition, vascular 
20 density was reduced and filtration layer markers collagen IV and nephrin (a marker of glomerular 
21 integrity) were dysregulated. Glial cell-line derived neurotrophic factor (GDNF), a known 
22 determinant of ureteric bud branching (27), was downregulated in early-symptomatic kidneys in this 
23 mouse model of severe SMA, and likely drives the dramatic decrease in nephron number described 
24 here. These data emphasise the need for early treatment of systemic defects, which will likely result 
25 in late morbidity if left unresolved.
































































2 Postnatal development is defective in kidneys from a mouse model of severe SMA 
3 No gross anatomical abnormalities in kidney were apparent at birth (P1: pre-symptomatic), but by 
4 P4 (early symptomatic) and P8 (late symptomatic) stages, there were notable variations in size and 
5 colour (Figure 1A). From P4 onwards, absolute kidney weight was significantly reduced in SMA mice 
6 compared with heterozygous control littermates (Het), **P <0.01 (Figure 1B). However, when kidney 
7 weight was expressed relative to body weight, there was a significant decrease in P4 SMA only 
8 (**P<0.01: Figure 1C), which is prior to the significant wasting and weight loss seen by P8. This is 
9 indicative of an intrinsic abnormality in kidney growth and development. Western blotting for SMN 
10 revealed a decrease of 68% (***P<0.001) in protein expression at early symptomatic P5, which 
11 further decreased to 82% (**P<0.01) of Het levels by late symptomatic P8 (Figure 1D and 
12 Supplementary Figure 1). Routine inspection of P8 H&E stained sections of kidney revealed no gross 
13 morphological abnormalities, however nephron density in SMA appeared to be low in comparison 
14 with Het kidney (Figure 1E-H). An increased renal capsular thickness in SMA mice was also noted, 
15 indicating fibrosis (Figure 2B and D). Further careful observation found accumulations of PAS-
16 positive, hyaline casts in glomeruli of kidneys from the SMA mouse model, which were completely 
17 absent in Het kidneys (Figure 1I-L). These structures are consistent with glomerular sclerosis and 
18 frequently associated with hypoplastic nephropathology, and therefore warranted further study. 
19
20 Nephron Number is Decreased in kidneys from the SMA mouse model
21 To properly assess nephron number, we turned to gold-standard, stereological methods. This 
22 systematic approach revealed a substantial and significant ~65% decrease in nephron number in 
23 kidneys from the SMA mouse model, compared with Het littermates (**P<0.01: Figure 2E). 
24 Specifically, kidneys from the SMA mouse model lacked nephrons in the most peripheral, cortical 
25 regions, where the youngest nephrons are found (Figure 2A-D), suggesting retarded nephrogenesis. 































































1 No nephrogenic debris, associated with nephron death and degeneration was present, suggesting a 
2 failure in nephron development.
3 These data suggest that low levels of SMN protein are associated with significantly decreased 
4 nephrogenesis in kidneys from the SMA mouse model. This is important, as such a decrease in 
5 nephron number cannot be compensated for postnatally. 
6
7 Ultrastructural changes are present in kidneys from the SMA mouse model
8 With the decrease in nephron number and evidence of glomerular sclerosis described above, we 
9 next investigated the ultrastructure of the multipartite, glomerular filtration layer. We first assessed 
10 the tripartite lamina of the glomerular basement membrane, made up of the podocyte foot 
11 processes of the Bowman’s capsule, collagen basement membrane and endothelial plasmalemma. 
12 We found increased evidence of localised areas of basal lamina lamellation in kidneys from the SMA 
13 mouse model at P5 (Fig 3A and C), however this was not significant in comparison with Het 
14 littermates, where some lamellation was also present. We next assessed podocytes and associated 
15 slit pores by quantifying the intersectional length between adjacent podocyte foot processes, and 
16 example images used for quantification are shown in Figure 3B and D. A small, but non-insignificant, 
17 decrease was apparent between mean slit length in Het and SMA groups, Figure 3E (ns, P>0.05). 
18 These observations may suggest early evidence of damage, associated with glomerular filtration 
19 defects, are present at the ultrastructural level at this early symptomatic stage.
20
21 Vascular Deficits are present in kidneys from the SMA mouse model
22 As vascular pathology is commonly described in a range of organs in both mouse models (5,28) and 
23 patients (29), we examined capillary beds in kidneys from the SMA mouse model. 
24 PECAM-1 (platelet endothelial cell adhesion marker-1) immunofluorescence of endothelial cells 
25 indicated a gross reduction in capillary density, including decreased staining in the inner medulla and 
26 disorganised architecture in the cortical regions of P8 kidneys from the SMA mouse model (Figure 4A 































































1 and D). Closer inspection revealed a decreased microvascular density in the cortex (Figure 4B and E), 
2 with a significant reduction of ~40% in PECAM-1 staining density in kidneys from the SMA mouse 
3 model relative to Het tissue, (***P< 0.001: Figure 4G). Whole tissue western blotting confirmed a 
4 continual decrease in PECAM-1 in kidneys from the SMA mouse model, with expression at P5 
5 decreased by 53.2% (*P<0.05) and further to 78.6% at P8 (***P<0.001), Figure 4H-I and 
6 Supplementary Figure 2. As PECAM-1 presents as 2 bands in all mice (Figure H and I), both bands 
7 were quantified to ensure the reliability of results.
8 Z-stacks of confocal images of nephrons, taken from similar areas to ensure they were at 
9 comparable stages of maturity, showed reduced glomerular capillary bed complexity in SMA 
10 nephrons. These had fewer capillary loops and were smaller in SMA model mice (Figure 4C and F). 
11 These observations suggest that the previously desribed pattern of reduced tissue vascularity and 
12 maturation is also a feature of kidney development, which likely further compromises renal function.
13
14 Slit diaphragm protein nephrin is dysregulated in kidneys from the SMA mouse model
15 Given the defects in the ultrastructure of the glomerular filtration membrane, we next investigated 
16 the molecular composition of this layer by staining for nephrin, a zipper-like protein that functions to 
17 maintain intersections between foot processes on the slit diaphragm (30). Nephrin expression is a 
18 biomarker for early podocyte injury, and loss has been shown to precede the development of 
19 glomerular lesions (31). Immunostaining revealed a dramatic reduction of almost 4-fold in 
20 expression of nephrin in individual mature glomeruli from kidneys from the SMA mouse model 
21 relative to Het (***P<0.001: Figure 5 A-C).
22 At a whole tissue level, western blotting revealed a ~30% decrease in nephrin expression at early-
23 symptomatic P5, and a later increase of ~30% above levels of Het littermates at P8, Figure 5D-E and 
24 Supplementary Figure 3. Given the ongoing developmental changes in the kidney at this time, it is 
25 perhaps not surprising that these differences were not significant (ns, P>0.05). This dysregulation is 
26 likely associated with the changes in the ultrastructure of the slit diaphragm described above, as 































































1 changes in nephrin expression are characterised by narrowing of the slits on the diaphragm and 
2 related to disturbance of protein ratio of the ultrafiltration barrier (32,33). 
3
4 Collagen IV is dysregulated in kidneys from the SMA mouse model
5 The basement membrane extracellular matrix protein collagen IV is dysregulated in many SMA 
6 tissues (5,14), and in the kidney functions as the second layer of filtration in the renal corpuscle. 
7 Immunofluorescence highlighted an altered distribution of collagen IV throughout kidneys from the 
8 SMA mouse model, with Het sections showing a regular and consistent expression in all basement 
9 membranes and a thin capsular layer surrounding the kidney. In contrast, kidneys from the SMA 
10 mouse model displayed a dramatic increase in the thickness of the collagen IV capsule, suggestive of 
11 fibrosis (Figure 6A and D). Conversely, intercellular, glomerular and tubular basement membranes 
12 displayed a decreased intensity of staining in SMA (Figure 6C-D and E-F). All photomicrographs were 
13 obtained using identical staining and image capture parameters to ensure consistency, and 
14 therefore variance in staining intensity is likely representative of changes in collagen IV expression.
15
16 Glial Cell-Line Derived Neurotrophic Factor (GDNF) expression is altered in early-symptomatic 
17 severe SMA model mice 
18 To characterise molecular factors underlying the observed structural alterations and assess 
19 expression of genes relevant for kidney development, we performed a quantitative real-time PCR 
20 screening with pooled kidney samples from Het and SMA model mice, specifically at early 
21 symptomatic stage P4 (Figure 7A). Three targets showed up- or down-regulation, respectively: the 
22 POU transcription factor Brn1 (POU Class 3 Homeobox 3, POU3F3), the transcription factor Paired 
23 box 2 (Pax2) and Glial cell-line derived neurotrophic factor (GDNF).  Targets were further analysed 
24 with cDNA samples from individual Het and SMA mice at P2 and P4 (Figure 7B). While Brn1 and Pax2 
25 did not show altered regulation, GDNF transcripts were significantly down-regulated at P4, but not 
26 at P2. We additionally analysed protein levels of GDNF in SMA and heterozygous control samples 































































1 (Fig. 7C-D) by Western blotting. Secreted GDNF has a relative molecular weight of 15 kDa, whereas 
2 an unprocessed pro-form shows a molecular weight of about 70 kDa as a dimer. Post-translational 
3 processing of GDNF has been described including proteolytic cleavage and N-linked glycosylation 
4 (34). Multiple comparison tests revealed a significant difference of 15 kDa GDNF for the genotype as 
5 source of variation. Interestingly, the GDNF pro-form was upregulated in samples from SMA mice 
6 indicating an additional level of regulation. However, both GDNF transcript and protein levels show a 
7 decrease. GDNF is important for kidney development, since reciprocal signalling between GDNF and 
8 its receptor Ret is crucial for ureteric bud branching and therefore establishing accurate kidney 
9 morphology (35). Taken together these data suggest molecular, structural and functional defects 
10 likely to lead to changes in kidney filtration and the onset of kidney sclerosis in SMA.
































































2 Spinal muscular atrophy (SMA) is a multisystem disease affecting most organs, which now includes 
3 the kidneys. Here, we report small kidneys, with a severely decreased nephron density and early 
4 signs of fibrosis and sclerosis, consistent with significant pathology in the renal system of severe 
5 SMA mice. Structural and ultrastructural defects were present, including reduced vascularity, 
6 dysregulation of key glomerular filtration barrier components nephrin and collagen IV, and evidence 
7 of basement membrane lamellation. Finally, we determined a decrease in expression of GDNF mRNA 
8 transcripts which may molecularly underpin the reduction in nephron density described. 
9
10 The small size of kidneys from the SMA mouse model at early-symptomatic age is indicative of an 
11 intrinsic abnormality in early postnatal renal development. During the first two days of murine 
12 postnatal life, the rate of nephrogenesis is accelerated and a large number of new nephrons are 
13 produced, as the ureteric bud extends to the most peripheral layers of the developing kidney (23). 
14 This surge allows previously vacant areas to be occupied and establishes the final characteristic renal 
15 structure. Additionally between days P4-6, a further accelerated period of growth allows maturation 
16 of existing nephrons (36). Lack of normal growth observed in kidneys from the SMA mouse model 
17 may be the outcome of a failure or delay in the final surge of nephrogenesis and subsequent 
18 maturation. Delayed growth in SMA patients and mouse models has been demonstrated in the 
19 neuromuscular system (37) and the liver (11), therefore a delay in renal development is also likely. 
20
21 Nephron number is prenatally determined in humans and in the early postnatal days in mice (22,23). 
22 Following termination of nephrogenesis, nephron number is at a maximum, and then gradually 
23 declines throughout life. We determined that SMA mice have a dramatic reduction in nephron 
24 density at P8, an age chosen to correlate with the formation of mature nephrogenic structures and 
25 therefore permitting accurate identification. Low nephron number in these mice is likely a 
26 consequence of genetic predisposition, as other factors associated with this pathology, including 































































1 intra-uterine growth restriction and low birth weight, are not characteristic of SMA (38–40). 
2 Microarray analysis of SMN patterning during renal development shows strong expression in the 
3 renal vesicle and weak expression in metanephric mesenchyme and S-shaped bodies (41), however 
4 its role in these stages of the developing nephron remains unknown. Kidneys from the SMA mouse 
5 model lacked nephrons in the most peripheral layers of the renal cortex, consistent with a delayed 
6 development hypothesis which may be explained by an inability of the ureteric bud to extend to the 
7 furthest cortical regions in the allocated timeframe. The decreased levels of GDNF mRNA and 
8 protein also reported may provide a causative link between SMN and low nephron density. 
9 Reciprocal signalling between GDNF (secreted by the metanephric blastema) and the Ret receptor 
10 (expressed in the ureteric bud) is crucial in the induction and continued branching of the ureteric 
11 bud, and is therefore a determinant of nephron density (27,35). GDNF loss or reduction is shown to 
12 cause formation of renal hypodysplasia (42), a phenotype reminiscent of the reduction in nephron 
13 density observed in these SMA model mice.
14
15 Investigation at the ultrastructural level uncovered evidence of localised areas of basal lamina 
16 lamination, more frequently observed in SMA mice. Lamellation is a common feature of Alport’s 
17 disease caused by defects in particular collagen IV isoforms, specifically α3, α4 and α5 chains, and 
18 results in proteinuria and progressive loss of kidney function (43,44). Dysregulation of collagen IV is 
19 commonly reported in SMA (5,14). In the kidney, collagen IV is a vital extracellular matrix protein of 
20 the basement membranes, important in maintaining the structural framework and acting as the 
21 second layer of filtration in the glomerulus (45). Intercellular glomerular and tubular basement 
22 membranes displayed decreased expression, indicating a defective layer with increased likelihood of 
23 proteinuria due to an abnormal glomerular basement membrane. Due to the young age of the SMA 
24 mouse model, we were unable to measure proteinuria and determine compromised renal 
25 functioning because of inadequate urine volume, but this has recently been described in patients 
26 (21). Collagen IV also constitutes the renal capsule, which was substantially thicker in the kidneys 































































1 from the SMA mouse model, indicating a fibrotic structure surrounding the organ. Together these 
2 findings suggest a significantly altered ultrafiltration layer which correlate with reports of proteinuria 
3 in patients (21).
4
5 Nephrin is an important regulator of kidney development, mediating podocyte maturation and 
6 maintaining glomerular structure and integrity throughout life (46,47). This transmembrane protein 
7 is localised to the slit diaphragm layer and constitutes a porous scaffold, with nephrin strands 
8 spanning between adjacent podocyte foot processes (33,48,49). Consistent with a previous study 
9 (33), our measurements of podocyte slit length revealed foot processes in Het mice separated by a 
10 ~35-40nm wide slit. Although not significant, a slight decrease in slit length in kidneys from the SMA 
11 mouse model was apparent. Depletion of this anchoring protein commonly causes narrowing of the 
12 slits and is associated with proteinuria as a result of podocyte detachment (33,47). We report 
13 dysregulation of nephrin expression in kidneys from the SMA mouse model, with tissue analysis 
14 revealing an early-symptomatic decrease in expression, which later increased to above that of 
15 heterozygous littermate controls. At the glomerular level, a profound decrease in staining intensity 
16 of nephrin was noted at a late-symptomatic stage. From these data we suggest the interplay of two 
17 important factors; [1] downregulation followed by a later increase in expression may be due to the 
18 mouse model itself, as an increase in pro-inflammatory cytokines IL-1B and TNFα is known to cause 
19 the upregulation of nephrin expression (32,50). In this Taiwanese model of SMA, pro-inflammatory 
20 cytokines are markedly increased from early-symptomatic stages representing systemic 
21 inflammation in the animal (51). We suggest that systemic inflammation, especially at later stages of 
22 disease progression, may result in a secondary increase in nephrin expression from initially low to 
23 ultimately high levels as detected by tissue analysis; [2]) Varying results between single glomerular 
24 and whole tissue expression at late-symptomatic stage may be the result of protein translocation 
25 from membrane to cytoplasm, as described in other nephropathies (31,52,53). In diseased states, 
26 nephrin expression shifts from a consistent and linear pattern to a granular distribution, less clearly 































































1 localised to the glomerular basement membrane, which would cause a diminished fluorescent signal 
2 in comparison with normal nephrin localisation. As both nephrin loss and redistribution have been 
3 shown to precede the development of glomerular lesions (31), dysregulation may provide early 
4 evidence of glomerular injury in SMA mice.
5
6 Vascular deficits were evident in kidneys from the SMA mouse model, corresponding with previous 
7 findings of depleted capillary density in other tissues in mouse models and patients (5,8,28,54,55). 
8 As highly vascular organs the kidneys must maintain intricate vascular networks critical for proper 
9 functioning. Kidneys from the SMA mouse model displayed a significant decrease in microvascular 
10 density, with reduced glomerular capillary bed complexity. Renal vascularisation occurs 
11 synchronously with nephrogenesis (56), therefore a delay in nephrogenic development may cause a 
12 subsequent delay in the development of the renal vessels. Differing reports of vascular defects in 
13 SMA are thought to be the result of tissue specific downstream effects of SMN deficiency on the 
14 vasculature itself, and are commonly associated with tissue hypoxia (4). Chronic hypoxia in the 
15 kidneys is a progressive accelerator of chronic renal disease, with decreased renal oxygenation 
16 leading to matrix accumulation and inflammatory response, causing fibrosis and ultimately end-
17 stage renal disease (57). The kidney, although well perfused, has poor oxygenation of the renal 
18 parenchyma due to its architecture and function (58). Further insult due to reduced capillary density 
19 in SMA may result in chronic hypoxia of the tissue, leading to initiation of a fibrotic cascade. The 
20 interplay of cardiac defects, low nephron number and decreased capillary density may cause a highly 
21 stressed renal environment, possibly culminating in hypertension and renal insufficiency in SMA.
22
23 Renal health and later prognosis are directly influenced by nephron number (59), and associations 
24 with blood pressure form the basis of understanding for hypertension and chronic kidney disease 
25 (60,61). Significant nephron deficits lead to a vicious cycle of further nephron loss through 
26 hypertrophy and hyperfiltration as remaining nephrons attempt to compensate, culminating in an 































































1 increasingly stressed renal environment (62). Consequences of a severe nephron deficit may not 
2 arise in young patients due to their small size and proportionally low blood volume, however with 
3 newly available therapies able to extend patient lifespan, renal pathology could manifest in later life. 
4 A deficit in nephron number, together with defects in the ultrafiltration layers indicate an organ with 
5 retarded development that will most likely result in functional deficits. Significantly, even with a 
6 systemic treatment administered as early as birth, no recovery of nephron density is possible due to 
7 the entirely embryonic timescale of nephrogenesis. This suggests that combinatorial, non SMN-
8 related therapy may be required to combat kidney pathology.
9
10 Conclusion
11 Renal pathology is present in a severe mouse model of SMA from early postnatal life, likely 
12 consequential of aberrant kidney development. In correlation with a recent study that has described 
13 functional changes in SMA patient kidneys (20), our findings characterise preclinical morphological 
14 and molecular changes that may be responsible for later functional outcomes. Kidney pathology may 
15 have been masked previously due to early disease fatality, however with new therapeutic options 
16 that extend patient lifespan available, consequences could manifest. These data provide evidence of 
17 additional systemic organ pathology in SMA and emphasise the need for systemic and combinatorial 
18 therapies.
19































































1 Materials and Methods
2 Taiwanese SMA Mouse Model and Tissue Processing
3 The Taiwanese mouse model of SMA represents a severe form of the disease (63,64). Taiwanese 
4 SMA mice were maintained as breeding pairs under standard scientific pathogen-free conditions in 
5 animal care facilities at the University of Edinburgh. All experimental protocols were approved by 
6 the University of Edinburgh research and ethics committee and carried out in accordance with a 
7 license from the United Kingdom Home Office under the Animals (Scientific Procedures) Act 1986. 
8 Offspring were homozygous for SMN Knockout, SMN-/-; SMN2tg/0, (SMA disease model) or 
9 heterozygous for SMN knockout, SMN+/-; SMN2tg/0 (control). Mice were retrospectively genotyped 
10 following standard PCR protocols. Day of birth was defined as postnatal day 1 (P1). Kidneys from 
11 experimental and control littermates were harvested at birth, P1/2; representing a pre-symptomatic 
12 stage, P4/5; early-symptomatic and P8; late-symptomatic, staged in terms of standard 
13 neuromuscular pathology. For histological analysis and immunofluorescence protocols, whole 
14 kidneys were dissected, fixed in 4% paraformaldehyde (PFA) for 4 hours and then stored in 
15 phosphate buffered saline (PBS). For western blotting, kidneys were submerged into dry ice 
16 immediately following dissection and stored at -80oC.  Both groups were then transferred to the 
17 Institute of Medical Sciences, University of Aberdeen. Paraffin wax embedded kidneys were 
18 sectioned (8µm) and stained with a standard haematoxylin and eosin protocol for initial histological 
19 assessment. 
20 For electron microscopy, kidneys were rapidly dissected to 1mm3 pieces in 4oC buffer (0.1M Na-
21 cacodylate buffer supplemented with 2 mM CaCl2, pH 7.4) and fragments were fixed in a solution of 
22 2% glutaraldehyde + 4% PFA in 0.1Na-Cacodylate buffer supplemented with 2mM CaCl2 for 24 hours.
23 For expression analyses by qRT-PCR, kidneys were collected from P2 and P4 control and SMA mice at 
24 Hannover Medical School. All experimental protocols followed German animal welfare law and were 
25 approved by the Lower Saxony State Office for Consumer Protection and food Safety (LAVES, 
26 approval number 15/1774). 
































































2 Stereological fractionator/dissector combination methods were employed to ensure an accurate 
3 estimation of nephron number. A pilot study was conducted to determine both the total number of 
4 sections through a kidney and the mean maximal glomerular diameter, to allow an optimum section 
5 sampling fraction and dissector height to be chosen. Paraffin embedded kidneys, P8 (n=3), were 
6 exhaustively sectioned (5µm) in a coronal plane, with collection of every 12th (“reference” section) 
7 and 13th section (“look-up” section). Sections were stained with a modified Periodic Acid Schiff 
8 protocol (10 minutes periodic acid, 30 minutes Schiffs reagent, counterstained with haematoxylin 
9 (Sigma-Aldrich, 395B-1KT)), imaged on a Zeiss AxioScan Z1 slide scanner, and analysed using ImageJ 
10 software with a grid overlain. “Reference” and “look-up” sections of each pair were compared and 
11 only newly appearing glomeruli were counted. Using Cavalieri’s principle, when multiplied by the 
12 inverse section sampling fraction provided an estimation of total glomerular number (65).
13
14 Immunofluorescence
15 Kidneys (P8) were cryopreserved in 30% sucrose solution with 0.1% sodium azide and embedded in 
16 a 1:1 solution of optimum cutting temperature compound (OCT) and 30% sucrose solution at -40°C. 
17 Coronal kidney sections (8µm) were air dried for 1 hour and underwent antigen retrieval by 
18 submersion in 10mM sodium citrate buffer at 90oC (20 minutes). Sections were incubated for 2 
19 hours in blocking solution (0.4% bovine serum albumin (BSA), 1% Triton X-100 in 0.1M PBS) at 4oC 
20 and then overnight with primary antibody; polyclonal guinea-pig anti-nephrin (Acris BP5030, 1:50), 
21 polyclonal rabbit anti-collagen IV (Millipore AB756P, 1:100), polyclonal goat anti-PECAM-1 (R&D 
22 AF3628, 1:100) at 4oC. Slides were washed three times (2x 10 minutes in PBT (0.1M phosphate 
23 buffered saline (PBS) with 0.1% Tween-20), and once in 0.1M PBS). Sections were incubated with 
24 corresponding secondary antibodies; Alexa Fluor 594 goat anti-guinea pig IgG (H+L) (Invitrogen 
25 A11076, 1:250), Cy3 goat anti-rabbit IgG (H+L) (Invitrogen A10520, 1:250), Alexa Fluor 488 donkey 
26 anti-goat IgG (H+L) (Abcam ab150129, 1:250) for 2 hours at 4oC, with successive washes as before. 































































1 Sections were mounted using MOWIOL media (10% Mowiol (Sigma-Alrich, 81381), 20% glycerol, 
2 50% 0.2M Tris buffer pH 8.5, 3% 1,4-diazobicyclooctance in distilled water) containing 4’,6-
3 diamidino-2-phenylindole (DAPI).
4 Immunofluorescent stained slides were imaged at various magnifications on an Upright Zeiss Imager 
5 M2 Fluorescent microscope (x4, x10 objectives) and Zeiss LSM710 inverted confocal microscope 




10 Density of nephrin staining was conducted on x63 magnification confocal images of 18 single 
11 nephrons of each genotype, from SMA and HET kidneys (n=3). Images were edited on Zen software 
12 to the same parameters to decrease background staining. Images were converted into binary using 
13 ImageJ. Stained area was encircled by the oval selection tool to represent the glomerular area. 
14 Histograms provided a pixel count expressing black pixels in relation to white pixels. Total nephrin 
15 stained area (black pixels) was calculated relative to total glomerular area (black and white pixels).
16
17 PECAM-1 Density
18 PECAM-1 staining was similarly quantified using ImageJ on x20 confocal images. PECAM-1 positive 
19 cell area (black pixels) was expressed as a percentage of total field of view area on ImageJ.
20
21 Semi-quantitative Western Blotting
22 Kidneys, P5 and P8 (n=4), were extracted in RIPA buffer (Thermo Fisher, 89900) containing 2.5% Halt 
23 protease inhibitor cocktail (Sigma-Aldrich, P8340) on ice for 20 minutes, homogenised and then 
24 centrifuged at 14,000g for 30 minutes at 4oC. BCA assay was carried out to quantify protein 
25 concentration of each sample. Tissue lysates were diluted to 2.5μg/μl and added to a 1:4 dilution 
26 with SDS-PAGE Loading sample buffer 4x. Wells were loaded with 50μg of tissue lysate protein. 































































1 Proteins were separated by SDS-polyacrylamide gel electrophoresis on NuPage 4-12% BisTris Gels 
2 during 1 hour at 160V, then transferred to Immobilon-FL transfer membrane for 90 minutes at 30V. 
3 Reversible total protein stain was carried out using Li-COR Revert total protein stain and wash 
4 solution (Li-COR, 926-11011). Membrane was reverted using 0.1% sodium hydroxide in 30% 
5 methanol. Membranes were submerged in blocking solution (1:1 Thermo Scientific Sea Block Buffer 
6 and PBST) at room temperature for 1 hour, then incubated overnight at 4oC with primary antibody; 
7 monoclonal mouse anti-SMN (BD, 610646, 1:1600), monoclonal rabbit anti-nephrin (Abcam 
8 ab216341, 1:5000), polyclonal rabbit anti-CD31(Abcam ab28364, 1:500). Membranes were washed 
9 (4x 5 minutes) in PBS, then incubated for 1 hour at room temperature with corresponding secondary 
10 antibody; IRDye® 800CW Goat anti-mouse (Li-COR 925-32210, 1:10,000) or IRDye® 680RD Goat anti-
11 rabbit (Li-COR 925-68071, 1:10,000). Membranes were washed as before and imaged using Li-COR 
12 Odyssey imaging system. Western blotting analysis was performed with Image Studio Lite Version 
13 5.2.
14 For analyses of GDNF expression levels, kidneys of SMA and heterozygous control animals were 
15 collected at postnatal days P2 and P4 and homogenized for 5 min with a TissueLyser II (Qiagen) using 
16 tungsten carbide beads (Qiagen) lysed in RIPA buffer [137 mM NaCl, 20 mM Tris-HCl pH 7, 525 mM 
17 β-glycerophosphate, 2 mM EDTA, 1 mM sodium-orthovanadate, 1% (w/v) sodium-desoxycholate, 1% 
18 (v/v) Triton-X-100, with phosphatase (1:20) and protease inhibitor (1:50) cocktails (Roche)]. Samples 
19 were then centrifuged at 4°C (22,000 rcf) for 15 min. Concentration of proteins was determined by 
20 Pierce™ bicinchonic acid (BCA) Protein Assay kit. Same amounts of the samples were analysed on 
21 Western blots after SDS-PAGE. The following antibodies were used: Primary antibodies, monoclonal 
22 mouse anti-SMN (BD, 610646, 1:4,000) and monoclonal mouse anti-GDNF (Santa Cruz, B-8, sc-
23 13147,1:500). Secondary antibody, HRP-linked anti-mouse IgG (GE Healthcare, 1:5,000). After 
24 western blotting, membranes were stained and imaged for subsequent densitometry and 
25 normalization. Before incubation with antibodies, blots were blocked with 5% (w/v) bovine serum 
26 albumin (BSA) in TBS-T. Detection of chemiluminescence was performed with Immobilon™ Western 































































1 HRP Substrate (Millipore). Densitometry of staining and chemiluminescent signal was carried out 
2 with LabImage 1 D (Intas). 
3
4 Transmission Electron Microscopy
5 Two randomly selected kidney fragments of each sample, P5 (n=4), were washed in 0.1M sodium 
6 cacodylate (pH7.4) (3x 5minutes), transferred into 1:1 solution of 2% osmium tetraoxide and 0.2M 
7 sodium cacodylate on ice for 2 hours and washed in distilled water (3x 10 minutes). Specimens were 
8 dehydrated through a series of alcohols and changes of propylene oxide (3x 5 minutes), then 
9 incubated overnight in 1:1 propylene oxide and Epon solution. Samples were submerged in 100% 
10 Epon resin for 24 hours, 100% Epon resin with accelerator for 24 hours and then embedded in Epon 
11 resin. To ensure correct region was identifiable in sample, semithin sections (1µm) were cut, stained 
12 with toluidine blue and examined under a light microscope. Only blocks with at least 3 mature and 
13 centrally located glomeruli were selected. Ultrathin sections (~90nm) were cut, collected on grids, 
14 stained with methanolic uranyl acetate (3 minutes) and lead citrate (3 minutes) and examined using 
15 a JEOL 1200 EX running at 80kV. Images were captured on a Cantega 2Kx2K camera using Olympus 
16 ITEM software. To select representative glomeruli, viewing of the section always began at the left 
17 side of the section and moved to the right. The entire grid was reviewed to identify medullary tissue. 
18 The first 3 glomeruli located in closest proximity to the medullary tissue represented the most 
19 mature and were used in analysis. If no medullary tissue was present, glomeruli were selected from 
20 the central region of the section. All peripheral glomeruli were discounted due to their immature 
21 stage. Analysis of podocyte coverage of the basement membrane was conducted on x5000 
22 magnification photomicrographs using ImageJ. Three regions of the podocyte layer adjacent to the 
23 Bowman’s basal lamina of each glomerulus was assessed (3 glomeruli per kidney), with 5 
24 consecutive images taken at each region. Regions imaged were equally distributed in the 
25 glomerulus. Using the freehand line tool, the total length of basement membrane visible and the 































































1 length of each podocyte was measured. Mean intersectional space between podocytes was 
2 calculated.
3
4 Quantitative real time PCR (qRT-PCR)
5 Total mRNA from kidneys, P2 and P4 (n≥3), was isolated using Qiagen RNeasy Plus Kit according to 
6 manufacturer´s instructions. cDNA synthesis and PCR was performed as previously described on 
7 StepOnePlus thermocycler (Applied Biosystems) (66). For normalisation, expression of the 
8 housekeeping gene peptidyl-prolyl cis-trans isomerase (Ppia) was used. The following primers were 
9 used (5´>3´): Pax2 (NM_011037.4) FWD GAAGCTACCCTACCTCCAC and REV 
10 GCACTATAATAATAAGGGGAACT, GDNF (NM_010275.2) FWD TGACCAGTGACTCCAATATGCC and REV 




15 Statistical analysis was carried out on GraphPad PRISM software (GraphPad Software Inc.). All data is 
16 presented as mean + SEM. Statistical testing utilised unpaired, two-tailed t-tests, where * <P0.05, ** 
17 <P0.01 and *** P<0.001. For analyses of qRT-PCRs, 2-way ANOVA with Holm-Sidak´s multiple 
18 comparisons test was used. 
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4 Abbreviations
5 SMA Spinal Muscular Atrophy
6 SMN Survival Motor Neuron protein
7 GDNF Glial cell-line derived neurotrophic factor
8 SMN1 Survival Motor Neuron gene 1
9 SMN2 Survival Motor Neuron gene 2
10 Het Heterozygous control littermates
11 PECAM-1 Platelet endothelial cell adhesion molecule 1
12 Brn1 POU Class 3 Homeobox 3
13 Pax2 Paired Box 2
14 IL1β Interleukin 1 Beta
15 TNFα Tumour necrosis factor alpha
16

































































3 Figure 1: Postnatal kidney development is defective in severe SMA mice. 
4 (A) Gross anatomy of kidneys, harvested from HET (left) and SMA (right) mice at pre-symptomatic 
5 (P1), early-symptomatic (P4) and late-symptomatic (P8) stages, respectively. Scale bar, 5mm. 
6 (B) Quantification of kidney weight from P1, P4 and P8 mice. (C) Quantification of kidney weight, 
7 relative to body weight from P1, P4 and P8 mice. P values were calculated using a two-tailed 
8 Student’s t-test. Error bars, mean + S.E.M. (n > 5 mice per group). (D) Relative SMN levels from 
9 quantified western blots at P5, ***P, and P8, **P. Error bars, mean + S.E.M. (n > 4 mice per group). 
10 (E-H) Representative light microscopy images of entire kidney sections stained with H&E from HET 
11 (E) and SMA (G) mice at P8, scale 200µm. Higher magnification images of kidney sections from HET 
12 (F) and SMA (H) P8 mice that show no gross morphological abnormalities, scale 100µm. (I-L) 
13 Representative photomicrographs of PAS-stained glomeruli from P8 mouse kidneys. (I) Typical 
14 healthy glomerulus in P8 HET kidney, (J-L) Glomeruli from kidneys of the SMA mouse model 
15 depicting varying degrees of glomerulosclerosis. Increasing accumulation of amorphous, pink, 
16 hyaline material shown from minor (J) to major (L), highlighted by asterisk (*). Scale 50µm.
17
18 Figure 2: Nephron number is decreased in kidneys from SMA mice
19
20 Representative micrographs of PAS stained, coronally sectioned kidneys from HET (A) and SMA (C) 
21 P8 mice, scale 0.5mm. Higher magnification images of cortical regions in HET (B) and SMA (D), scale 
22 300µm. Insert depicts lack of nephrons in the peripheral cortex of kidneys from SMA mice and arrow 
23 points to thickened renal capsule, scale 150µm. (E) Quantification of nephron number in kidneys of 
24 P8 HET and SMA mice, **P. P values were calculated using a two-tailed Student’s t-test. Error bars, 
25 mean + S.E.M. (n =3 mice per group).
26
27 Figure 3: Ultrastructural changes are present in kidneys from SMA mice































































1 Electron micrographs of the basement membrane and podocyte foot processes from P5 kidneys 
2 from HET (A) and SMA (C) mice. In (A), black arrows show adjacent foot processes from a single 
3 podocyte. The basal lamina is highlighted by an asterisk (*). The white arrow in (C) points to a 
4 representative region of glomerular basement lamellation in kidneys from the SMA group. 
5 Representative images of P5 kidneys from HET (B) and SMA (D) mice, of podocyte foot processes 
6 and underlying basal lamina from which measurements of slit pore length were conducted. Scale 
7 500nm. (E) Quantification of slit membrane length in HET and SMA animals, P=ns. P values were 
8 calculated using a two-tailed Student’s t-test. Error bars, mean + S.E.M. (n=4 mice per group).
9
10 Figure 4: Vascular deficits are evident in kidneys from SMA mice
11 Representative immunohistochemistry of kidneys from P8 mice, HET (A-C) and SMA (D-F), stained 
12 with platelet endothelial cell adhesion marker-1 (PECAM-1). Overview of renal microvasculature in 
13 kidneys from HET (A) and SMA (D) P8 mice, highlighting reduction in capillary density and 
14 disorganised architecture of vessels, scale 200µm. Higher magnification depicts decreased staining 
15 density of renal cortex in SMA (E) compared with HET (B), scale 50µm.  Representative z-stack 
16 micrographs of glomerular capillary structure in kidneys from HET (C) and SMA (F) animals, depicting 
17 less structurally complex capillary loops in SMA mice, scale 10µm. (G) Quantification of staining 
18 intensity of PECAM-1. (H-I) Total PECAM-1 protein levels analysed by western blot and normalised to 
19 total protein at ages P5 (H), *P, and P8 (I), ***P. P values were calculated using a two-tailed 
20 Student’s t-test. Error bars, mean + S.E.M. (n >3 mice per group).
21
22 Figure 5: Slit diaphragm protein Nephrin is abnormal in kidneys from SMA mice
23 Representative immunohistochemistry of kidneys from P8 mice, HET (A) and SMA (B), mature 
24 glomeruli are labelled with Nephrin, scale 10µm. (A1-B1) Pixels reversed to show stained (black) area 
25 of the glomerulus, encircled to represent glomerular area compared to unstained (white) 
26 background from kidneys of P8 HET (A1) and SMA (B1) mice. (C) Quantification of Nephrin stained 































































1 area. (D-E) Total Nephrin protein levels analysed by western blot and normalised to total protein, at 
2 ages P5 (D) and P8 (E), P=ns. P values were calculated using a two-tailed Student’s t-test. Error bars, 
3 mean + S.E.M. (n >3 mice per group).
4
5 Figure 6: Collagen IV is dysregulated in kidneys from SMA mice
6 Representative immunohistochemistry of kidneys from P8 mice, HET (A-C) and SMA (D-F), stained 
7 with collagen IV. (A and D) Overview of renal cortex and renal capsule. (D) Increased staining density 
8 of the renal capsule in kidneys from SMA mice compared to HET (A), scale 100µm. (B and E) Internal 
9 glomerular and tubular basement membrane staining density is decreased in kidneys from SMA 
10 mice (E), compared to HET (B), scale 50µm. (C and F) Photomicrographs of single glomeruli also 
11 further highlight loss of collagen IV expression in glomerular basement membrane in kidneys from 
12 SMA mice (F), compared to Het littermates (C), scale 10µm.
13
14 Figure 7: Pre-symptomatic expression of genes and proteins relevant for kidney development
15 (A) Expression of targets for developmentally-relevant factors were pre-selected by a screening in 
16 heterozygous control (HET) and SMA mouse kidneys at P4 by quantitative real time PCR (qRT-PCR). 
17 For the screening, pooled samples (for number of samples in the pool, see n-values below) from 
18 several mice and litters were used in order to reveal targets with fold changes > 1.5 or < 0.6. Since 
19 we applied a screening approach in pooled samples first, no standard deviations were calculated. (B) 
20 Three factors found to be regulated in the screening were further analysed by qRT-PCR in individual 
21 tissue samples at P2 and P4. Glial cell-line derived growth factor (GDNF) was significantly down-
22 regulated in SMA mice at P4. *P; 2-way ANOVA; Holm-Sidak´s multiple comparisons test; P2 control 
23 n=5, P2 SMA n=3, P4 control n=5, P4 SMA n=6. (C) GDNF and SMN protein expression was analysed 
24 by Western blotting in HET and SMA kidney samples. Processed GDNF with a relative molecular 
25 weight (M) of 15 kDa and an unprocessed pro-form of GDNF (70 kDa) were both detected. 































































1 (D) For normalization, membranes were stained with Ponceau S. (D) Densitometic analyses of signals 
2 revealed down-regulation of 15 kDa GDNF in SMA samples compared to HER (2way ANOVA with 
3 Sidak´s multiple comparisons; significant for genotype as source of variation, *P, n=6 for each HET 
4 and SMA). Moreover, the GDNF pro-form showed an significant upregulation (2way ANOVA with 
5 Sidak´s multiple comparisons; significant for genotype as source of variation, **P, n=6 for each HET 
6 and SMA; also significant for P4 as time point with *P) indicating an additonal level of regulation by 
7 differential proteolytic processing.
8
9 Supplementary Figure 1: SMN Semi-Quantitative Western Blot
10 Uncropped blots for detection of SMN expression in Het controls and kidneys from SMA mouse 
11 model in P5 (A) and P8 (B) animals. Molecular weight of SMN is labelled as 40kDa. Total protein stain 
12 was used for normalisation of protein levels and is shown for kidneys from Het controls and SMA 
13 mouse model at P5 (C) and P8 (D). n=4 mice per group.
14
15 Supplementary Figure 2: PECAM-1 Semi-Quantitative Western Blot
16 Uncropped blots for detection of PECAM-1 expression in Het controls and kidneys from SMA mouse 
17 model in P5 (A) and P8 (B) animals. Molecular weight of SMN is labelled as 130kDa. Boxes highlight 
18 area of band quantified in HET 1 and SMA 1 lanes. Both the dominant band and the minor band 
19 below was quantified for all lanes. Total protein stain was used for normalisation of protein levels 
20 and is shown for kidneys from Het controls and SMA mouse model at P5 (C) and P8 (D). n=4 mice per 
21 group.
22
23 Supplementary Figure 3: Nephrin Semi-Quantitative Western Blot
24 Uncropped blots for detection of Nephrin expression in Het controls and kidneys from SMA mouse 
25 model in P5 (A) and P8 (B) animals. Molecular weight of SMN is labelled as 37kDa. Total protein stain 































































1 was used for normalisation of protein levels and is shown for kidneys from Het controls and SMA 
2 mouse model at P5 (C) and P8 (D). n=4 mice per group.
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Figure 1: Postnatal kidney development is defective in severe SMA mice. 
(A) Gross anatomy of kidneys, harvested from HET (left) and SMA (right) mice at pre-symptomatic (P1), 
early-symptomatic (P4) and late-symptomatic (P8) stages, respectively. Scale bar, 5mm. 
(B) Quantification of kidney weight from P1, P4 and P8 mice. (C) Quantification of kidney weight, relative to 
body weight from P1, P4 and P8 mice. P values were calculated using a two-tailed Student’s t-test. Error 
bars, mean + S.E.M. (n > 5 mice per group). (D) Relative SMN levels from quantified western blots at P5, 
***P, and P8, **P. Error bars, mean + S.E.M. (n > 4 mice per group). (E-H) Representative light 
microscopy images of entire kidney sections stained with H&E from HET (E) and SMA (G) mice at P8, scale 
200µm. Higher magnification images of kidney sections from HET (F) and SMA (H) P8 mice that show no 
gross morphological abnormalities, scale 100µm. (I-L) Representative photomicrographs of PAS-stained 
glomeruli from P8 mouse kidneys. (I) Typical healthy glomerulus in P8 HET kidney, (J-L) Glomeruli from 
kidneys of the SMA mouse model depicting varying degrees of glomerulosclerosis. Increasing accumulation 
of amorphous, pink, hyaline material shown from minor (J) to major (L), highlighted by asterisk (*). Scale 
50µm. 
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Figure 2: Nephron number is decreased in kidneys from SMA mice 
Representative micrographs of PAS stained, coronally sectioned kidneys from HET (A) and SMA (C) P8 mice, 
scale 0.5mm. Higher magnification images of cortical regions in HET (B) and SMA (D), scale 300µm. Insert 
depicts lack of nephrons in the peripheral cortex of kidneys from SMA mice and arrow points to thickened 
renal capsule, scale 150µm. (E) Quantification of nephron number in kidneys of P8 HET and SMA mice, **P. 
P values were calculated using a two-tailed Student’s t-test. Error bars, mean + S.E.M. (n =3 mice per 
group). 
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Figure 3: Ultrastructural changes are present in kidneys from SMA mice 
Electron micrographs of the basement membrane and podocyte foot processes from P5 kidneys from HET 
(A) and SMA (C) mice. In (A), black arrows show adjacent foot processes from a single podocyte. The basal 
lamina is highlighted by an asterisk (*). The white arrow in (C) points to a representative region of 
glomerular basement lamellation in kidneys from the SMA group. Representative images of P5 kidneys from 
HET (B) and SMA (D) mice, of podocyte foot processes and underlying basal lamina from which 
measurements of slit pore length were conducted. Scale 500nm. (E) Quantification of slit membrane length 
in HET and SMA animals, P=ns. P values were calculated using a two-tailed Student’s t-test. Error bars, 
mean + S.E.M. (n=4 mice per group). 
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Figure 4: Vascular deficits are evident in kidneys from SMA mice 
Representative immunohistochemistry of kidneys from P8 mice, HET (A-C) and SMA (D-F), stained with 
platelet endothelial cell adhesion marker-1 (PECAM-1). Overview of renal microvasculature in kidneys from 
HET (A) and SMA (D) P8 mice, highlighting reduction in capillary density and disorganised architecture of 
vessels, scale 200µm. Higher magnification depicts decreased staining density of renal cortex in SMA (E) 
compared with HET (B), scale 50µm.  Representative z-stack micrographs of glomerular capillary structure 
in kidneys from HET (C) and SMA (F) animals, depicting less structurally complex capillary loops in SMA 
mice, scale 10µm. (G) Quantification of staining intensity of PECAM-1. (H-I) Total PECAM-1 protein levels 
analysed by western blot and normalised to total protein at ages P5 (H), *P, and P8 (I), ***P. P values were 
calculated using a two-tailed Student’s t-test. Error bars, mean + S.E.M. (n >3 mice per group). 
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Figure 5: Slit diaphragm protein Nephrin is abnormal in kidneys from SMA mice 
Representative immunohistochemistry of kidneys from P8 mice, HET (A) and SMA (B), mature glomeruli are 
labelled with Nephrin, scale 10µm. (A1-B1) Pixels reversed to show stained (black) area of the glomerulus, 
encircled to represent glomerular area compared to unstained (white) background from kidneys of P8 HET 
(A1) and SMA (B1) mice. (C) Quantification of Nephrin stained area. (D-E) Total Nephrin protein levels 
analysed by western blot and normalised to total protein, at ages P5 (D) and P8 (E), P=ns. P values were 
calculated using a two-tailed Student’s t-test. Error bars, mean + S.E.M. (n >3 mice per group). 
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Figure 6: Collagen IV is dysregulated in kidneys from SMA mice 
Representative immunohistochemistry of kidneys from P8 mice, HET (A-C) and SMA (D-F), stained with 
collagen IV. (A and D) Overview of renal cortex and renal capsule. (D) Increased staining density of the 
renal capsule in kidneys from SMA mice compared to HET (A), scale 100µm. (B and E) Internal glomerular 
and tubular basement membrane staining density is decreased in kidneys from SMA mice (E), compared to 
HET (B), scale 50µm. (C and F) Photomicrographs of single glomeruli also further highlight loss of collagen 
IV expression in glomerular basement membrane in kidneys from SMA mice (F), compared to Het 
littermates (C), scale 10µm. 
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Figure 7: Pre-symptomatic expression of genes and proteins relevant for kidney development 
(A) Expression of targets for developmentally-relevant factors were pre-selected by a screening in 
heterozygous control (HET) and SMA mouse kidneys at P4 by quantitative real time PCR (qRT-PCR). For the 
screening, pooled samples (for number of samples in the pool, see n-values below) from several mice and 
litters were used in order to reveal targets with fold changes > 1.5 or < 0.6. Since we applied a screening 
approach in pooled samples first, no standard deviations were calculated. (B) Three factors found to be 
regulated in the screening were further analysed by qRT-PCR in individual tissue samples at P2 and P4. Glial 
cell-line derived growth factor (GDNF) was significantly down-regulated in SMA mice at P4. *P; 2-way 
ANOVA; Holm-Sidak´s multiple comparisons test; P2 control n=5, P2 SMA n=3, P4 control n=5, P4 SMA 
n=6. (C) GDNF and SMN protein expression was analysed by Western blotting in HET and SMA kidney 
samples. Processed GDNF with a relative molecular weight (M) of 15 kDa and an unprocessed pro-form of 
GDNF (70 kDa) were both detected. 
(D) For normalization, membranes were stained with Ponceau S. (D) Densitometic analyses of signals 
revealed down-regulation of 15 kDa GDNF in SMA samples compared to HER (2way ANOVA with Sidak´s 






























































multiple comparisons; significant for genotype as source of variation, *P, n=6 for each HET and SMA). 
Moreover, the GDNF pro-form showed an significant upregulation (2way ANOVA with Sidak´s multiple 
comparisons; significant for genotype as source of variation, **P, n=6 for each HET and SMA; also 
significant for P4 as time point with *P) indicating an additonal level of regulation by differential proteolytic 
processing. 
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Supplementary Figure 1: SMN Semi-Quantitative Western Blot 
Uncropped blots for detection of SMN expression in Het controls and kidneys from SMA mouse model in P5 
(A) and P8 (B) animals. Molecular weight of SMN is labelled as 40kDa. Total protein stain was used for 
normalisation of protein levels and is shown for kidneys from Het controls and SMA mouse model at P5 (C) 
and P8 (D). n=4 mice per group. 
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Supplementary Figure 2: PECAM-1 Semi-Quantitative Western Blot 
Uncropped blots for detection of PECAM-1 expression in Het controls and kidneys from SMA mouse model in 
P5 (A) and P8 (B) animals. Molecular weight of SMN is labelled as 130kDa. Boxes highlight area of band 
quantified in HET 1 and SMA 1 lanes. Both the dominant band and the minor band below was quantified for 
all lanes. Total protein stain was used for normalisation of protein levels and is shown for kidneys from Het 
controls and SMA mouse model at P5 (C) and P8 (D). n=4 mice per group. 
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Supplementary Figure 3: Nephrin Semi-Quantitative Western Blot 
Uncropped blots for detection of Nephrin expression in Het controls and kidneys from SMA mouse model in 
P5 (A) and P8 (B) animals. Molecular weight of SMN is labelled as 37kDa. Total protein stain was used for 
normalisation of protein levels and is shown for kidneys from Het controls and SMA mouse model at P5 (C) 
and P8 (D). n=4 mice per group. 
180x130mm (300 x 300 DPI) 
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